Literature DB >> 20118963

Antiplatelet therapies for the treatment of cardiovascular disease.

Alan D Michelson1.   

Abstract

Antiplatelet therapy has been successful in reducing mortality and morbidity in acute myocardial infarction. Recent advances in understanding the molecular basis of the role of platelets in cardiovascular thrombosis have enabled the development of new agents with the potential to further reduce mortality and morbidity. This article reviews the role of platelets in haemostasis and cardiovascular thrombosis, and discusses the benefits and limitations of current and investigational antiplatelet agents in the treatment of cardiovascular disease.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20118963     DOI： 10.1038/nrd2957

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  128 in total

1.  Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.

Authors:  D P Chew; D L Bhatt; S Sapp; E J Topol
Journal:  Circulation       Date:  2001-01-16       Impact factor: 29.690

2.  Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Carlo Patrono; Colin Baigent; Jack Hirsh; Gerald Roth
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

3.  An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia.

Authors:  A T Nurden; J P Caen
Journal:  Br J Haematol       Date:  1974-10       Impact factor: 6.998

4.  GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.

Authors:  M I Furman; L A Krueger; A L Frelinger; M R Barnard; M A Mascelli; M T Nakada; A D Michelson
Journal:  Thromb Haemost       Date:  2000-09       Impact factor: 5.249

5.  Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.

Authors:  Christopher P Cannon; Steen Husted; Robert A Harrington; Benjamin M Scirica; Håkan Emanuelsson; Gary Peters; Robert F Storey
Journal:  J Am Coll Cardiol       Date:  2007-10-23       Impact factor: 24.094

6.  A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex.

Authors:  Hiroshi Takayama; Yoshitaka Hosaka; Kazuyuki Nakayama; Kamon Shirakawa; Katsuki Naitoh; Tomokazu Matsusue; Mikihiko Shinozaki; Motoyasu Honda; Yukiko Yatagai; Tetsushi Kawahara; Jiro Hirose; Tooru Yokoyama; Michiru Kurihara; Shoji Furusako
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

7.  Acetylation of prostaglandin synthase by aspirin.

Authors:  G J Roth; N Stanford; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

8.  Interaction between cigarette smoking and clinical benefit of clopidogrel.

Authors:  Nihar R Desai; Jessica L Mega; Songtao Jiang; Christopher P Cannon; Marc S Sabatine
Journal:  J Am Coll Cardiol       Date:  2009-04-14       Impact factor: 24.094

9.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal:  Lancet       Date:  2008-12-26       Impact factor: 79.321

10.  Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.

Authors:  Stephen D Wiviott; Eugene Braunwald; Dominick J Angiolillo; Simha Meisel; Anthony J Dalby; Freek W A Verheugt; Shaun G Goodman; Ramon Corbalan; Drew A Purdy; Sabina A Murphy; Carolyn H McCabe; Elliott M Antman
Journal:  Circulation       Date:  2008-08-31       Impact factor: 29.690
View more
  100 in total

Review 1.  Arterial thrombosis--insidious, unpredictable and deadly.

Authors:  Shaun P Jackson
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

2.  Aspirin plus ticlopidine prevented experimental endocarditis due to Enterococcus faecalis and Streptococcus gallolyticus.

Authors:  Tiago Rafael Veloso; Frank Oechslin; Yok-Ai Que; Philippe Moreillon; José Manuel Entenza; Stefano Mancini
Journal:  Pathog Dis       Date:  2015-08-26       Impact factor: 3.166

Review 3.  The evolution of antiplatelet therapy in cardiovascular disease.

Authors:  Omair Yousuf; Deepak L Bhatt
Journal:  Nat Rev Cardiol       Date:  2011-07-12       Impact factor: 32.419

4.  The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy.

Authors:  Moritz Stolla; Lucia Stefanini; R Claire Roden; Massiel Chavez; Jessica Hirsch; Teshell Greene; Timothy D Ouellette; Sean F Maloney; Scott L Diamond; Mortimer Poncz; Donna S Woulfe; Wolfgang Bergmeier
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

5.  Prognostic Value of Controlled Attenuation Parameter by Transient Elastography.

Authors:  Ken Liu; Vincent Wai-Sun Wong; Keith Lau; Sienna Du Liu; Yee-Kit Tse; Terry Cheuk-Fung Yip; Raymond Kwok; Alex Yiu-Wa Chan; Henry Lik-Yuen Chan; Grace Lai-Hung Wong
Journal:  Am J Gastroenterol       Date:  2017-10-31       Impact factor: 10.864

6.  Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis.

Authors:  Christoph Klatt; Irena Krüger; Saskia Zey; Kim-Jürgen Krott; Martina Spelleken; Nina Sarah Gowert; Alexander Oberhuber; Lena Pfaff; Wiebke Lückstädt; Kerstin Jurk; Martin Schaller; Hadi Al-Hasani; Jürgen Schrader; Steffen Massberg; Konstantin Stark; Hubert Schelzig; Malte Kelm; Margitta Elvers
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

7.  Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome?

Authors:  M A Berny-Lang; C E Darling; A L Frelinger; M R Barnard; C S Smith; A D Michelson
Journal:  Int J Lab Hematol       Date:  2014-05-08       Impact factor: 2.877

Review 8.  Amicus or Adversary Revisited: Platelets in Acute Lung Injury and Acute Respiratory Distress Syndrome.

Authors:  Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman
Journal:  Am J Respir Cell Mol Biol       Date:  2018-07       Impact factor: 6.914

Review 9.  Systems biology of platelet-vessel wall interactions.

Authors:  Yolande Chen; Seth Joel Corey; Oleg V Kim; Mark S Alber
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 10.  Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Authors:  Kamila Bledzka; Susan S Smyth; Edward F Plow
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.